% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Dummer:276785,
      author       = {R. Dummer and K. T. Flaherty and C. Robert and A. Arance
                      and J. W. B de Groot and C. Garbe and H. J. Gogas and R.
                      Gutzmer and I. Krajsová and G. Liszkay and C. Loquai and M.
                      Mandalà and D. Schadendorf$^*$ and N. Yamazaki and A. d.
                      Pietro and J. Cantey-Kiser and M. Edwards and P. A.
                      Ascierto},
      title        = {{COLUMBUS} 5-year update: a randomized, open-label, phase
                      {III} trial of encorafenib plus binimetinib versus
                      vemurafenib or encorafenib in patients with {BRAF}.},
      journal      = {Future oncology},
      volume       = {19},
      number       = {16},
      issn         = {1479-6694},
      address      = {London},
      publisher    = {Future Medicine Ltd},
      reportid     = {DKFZ-2023-01160},
      pages        = {1091-1098},
      year         = {2023},
      note         = {2023 May;19(16):1091-1098},
      abstract     = {Here, we summarize the 5-year results from part 1 of the
                      COLUMBUS clinical study, which looked at the combination
                      treatment of encorafenib plus binimetinib in people with a
                      specific type of skin cancer called melanoma. Encorafenib
                      (BRAFTOVI®) and binimetinib (MEKTOVI®) are medicines used
                      to treat a type of melanoma that has a change in the BRAF
                      gene, called advanced or metastatic BRAF V600-mutant
                      melanoma. Participants with advanced or metastatic BRAF
                      V600-mutant melanoma took either encorafenib plus
                      binimetinib together (COMBO group), compared with
                      encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®)
                      alone (VEMU group).In this 5-year update, more participants
                      in the COMBO group were alive for longer without their
                      disease getting worse after 5 years than those in the VEMU
                      and ENCO groups. Patients in the COMBO group were alive for
                      longer without their disease getting worse when they: Had
                      less advanced cancer Were able to do more daily activities
                      Had normal lactate dehydrogenase (LDH) levels Had fewer
                      organs with tumors before treatment After treatment, fewer
                      participants in the COMBO group received additional
                      anticancer treatment than participants in the VEMU and ENCO
                      groups. The number of participants who reported severe side
                      effects was similar for each treatment. The side effects
                      caused by the drugs in the COMBO group decreased over
                      time.Overall, this 5-year update confirmed that people with
                      BRAF V600-mutant melanoma that has spread to other parts of
                      the body and who took encorafenib plus binimetinib were
                      alive for longer without their disease getting worse than
                      those who took vemurafenib or encorafenib alone. Clinical
                      Trial Registration: NCT01909453 (ClinicalTrials.gov).},
      subtyp        = {Review Article},
      keywords     = {BRAF V600 (Other) / BRAF inhibitor (Other) / COLUMBUS
                      (Other) / COLUMBUS part 1 (Other) / MEK inhibitor (Other) /
                      binimetinib (Other) / encorafenib (Other) / melanoma (Other)
                      / plain language summary (Other) / vemurafenib (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37309702},
      doi          = {10.2217/fon-2022-1258},
      url          = {https://inrepo02.dkfz.de/record/276785},
}